Clinical trial · no report yet · Phase 2
COPERNICUS
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- NCT06667076 ↗
- Recruiting
- Janssen Research & Development, LLC
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab; Lazertinib; Chemotherapy: Pemetrexed; Chemotherapy: Carboplatin
- Arms
- Cohort 1: Amivantamab and Lazertinib · Experimental
- Cohort 2: Amivantamab and Chemotherapy · Experimental
- Enrollment
- 480 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Dec 16, 2024
- Primary completion
- May 23, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06667076 · updated Sep 25, 2026